Clinical Neurofeedback Solutions Market Forecasts to 2034– Global Analysis By Type (EEG Clinical Neurofeedback Solutions, fNIRS Clinical Neurofeedback Solutions, HEG Clinical Neurofeedback Solutions and Other Types), Application, End User and By Geography
According to Stratistics MRC, the Global Clinical Neurofeedback Solutions Market is accounted for $1.55 billion in 2026 and is expected to reach $2.73 billion by 2034 growing at a CAGR of 7.3% during the forecast period. Clinical Neurofeedback Solutions refer to advanced therapeutic systems that utilize real-time monitoring of brainwave activity to train individuals in self-regulating neural functions. These solutions employ electroencephalography (EEG)-based technologies combined with specialized software to provide feedback that helps improve cognitive performance, emotional regulation, and behavioral outcomes. Widely used in the management of neurological and psychological conditions such as ADHD, anxiety, and sleep disorders, they are delivered through clinics and specialized centers. Clinical neurofeedback solutions support non-invasive, personalized treatment approaches, enhancing brain function through repeated conditioning and adaptive learning protocols.
Market Dynamics:
Driver:
Rising burden of neurological and mental health disorders
The growing prevalence of neurological and mental health conditions, including ADHD, anxiety, depression, and insomnia, is significantly driving demand for Clinical Neurofeedback Solutions. Increasing awareness of non-invasive and drug-free treatment alternatives has encouraged both patients and healthcare providers to adopt neurofeedback therapies. Additionally, rising stress levels, urban lifestyles, and improved diagnostic capabilities are contributing to higher diagnosis rates. This expanding patient pool, combined with a shift toward personalized and preventive care, continues to strengthen market growth globally.
Restraint:
High cost of devices and therapy
The high cost associated with Clinical Neurofeedback Solutions and therapy sessions remains a key restraint for market expansion. Advanced EEG-based systems require sophisticated hardware, software integration, and professional expertise, leading to elevated pricing. Furthermore, multiple therapy sessions are often needed to achieve desired outcomes, increasing the overall treatment cost for patients. Limited insurance coverage and reimbursement policies in many regions further restrict accessibility. These financial barriers particularly impact adoption in developing economies.
Opportunity:
Technological advancements in brain monitoring
Continuous advancements in brain monitoring technologies present significant opportunities for the market. Innovations in wearable EEG systems, artificial intelligence, and real-time data analytics are enhancing device accuracy, usability, and patient comfort. The integration of mobile applications and cloud-based platforms enables remote monitoring and personalized therapy, expanding access beyond clinical settings. These developments are fostering the emergence of home-based neurofeedback solutions, reducing dependency on healthcare facilities and creating new growth avenues for manufacturers and service providers.
Threat:
Regulatory hurdles and approval delays
Stringent regulatory requirements and prolonged approval timelines pose a major threat to the market. Medical device regulations vary across regions, requiring extensive clinical validation, safety assessments, and compliance documentation. These processes can delay product launches and increase development costs for manufacturers. Additionally, the lack of standardized protocols for neurofeedback therapy raises concerns regarding efficacy and consistency. Such regulatory complexities may discourage new entrants and slow innovation, thereby limiting the overall pace of market expansion.
Covid-19 Impact:
The COVID-19 pandemic had a mixed impact on the market. While initial disruptions in supply chains and reduced clinical visits hindered device adoption, the growing focus on mental health during the pandemic created new opportunities. Increased cases of anxiety, stress, and sleep disorders drove demand for non-invasive therapeutic solutions. Additionally, the shift toward telehealth and remote care accelerated the adoption of home-based neurofeedback systems. This transition highlighted the importance of digital health technologies, supporting long term market growth despite short term challenges.
The HEG Clinical Neurofeedback Solutions segment is expected to be the largest during the forecast period
The HEG Clinical Neurofeedback Solutions segment is expected to account for the largest market share during the forecast period, due to its cost effectiveness and ease of use compared to traditional EEG-based systems. HEG devices measure blood flow and oxygenation in the brain, offering a simpler and more accessible approach to neurofeedback therapy. Their growing adoption in cognitive training, stress management, and educational settings is driving segment growth. Additionally, reduced technical complexity and increasing availability in home based applications further contribute to their widespread utilization.
The epilepsy segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the epilepsy segment is predicted to witness the highest growth rate, due to increasing prevalence of seizure disorders and the need for non-pharmacological treatment options. Neurofeedback therapy offers promising benefits in regulating abnormal brainwave activity associated with epilepsy, reducing seizure frequency in some patients. Growing awareness among healthcare professionals and patients regarding alternative therapies is supporting adoption. Furthermore, ongoing research and clinical studies validating neurofeedback efficacy in epilepsy management are expected to accelerate growth.
Region with largest share:
During the forecast period, the North America region is expected to hold the largest market share, due to rising awareness of mental health, and improving healthcare infrastructure. Rapid urbanization and increasing stress-related disorders are contributing to higher demand for neurofeedback therapies. Additionally, growing investments in healthcare technology, expanding private healthcare facilities, and supportive government initiatives are fostering market growth. The increasing availability of affordable devices and services in emerging economies further strengthens the region’s dominant position.
Region with highest CAGR:
Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, owing to increasing healthcare expenditure, and expanding access to advanced treatment solutions. The rising penetration of digital health platforms and growing acceptance of home-based neurofeedback systems are key growth drivers. Additionally, a strong focus on early diagnosis and preventive healthcare, coupled with a large underserved population, creates significant growth opportunities. Continuous innovation and increasing investments by global and regional players further accelerate market expansion in the region.
Key players in the market
Some of the key players in Clinical Neurofeedback Solutions Market include BrainMaster Technologies, Inc., Thought Technology Ltd., Mind Media B.V., NeuroSky, Inc., Emotiv Inc., Neuroelectrics Corporation, Mitsar Co. Ltd., BEE Medic GmbH, Myndlift Ltd., Muse (InteraXon Inc.), Wearable Sensing, NeuroCare Group GmbH, ANT Neuro B.V., Advanced Brain Monitoring, Inc. and BrainCo, Inc.
Key Developments:
In October 2025, Inception partnered with Brain Co. to co-develop scalable and explainable AI products for enterprises, combining applied research with advanced AI platforms. The collaboration focuses on sectors like healthcare, energy, and public services, delivering trusted, high-impact solutions that enhance decision-making and operational efficiency.
In January 2025, Neuro XR (NXR) partnered with Emotiv to launch emotional heat-mapping technology that combines advanced analytics with EEG data. The solution delivers real-time insights into user emotions, integrating eye-tracking and movement mapping to enhance decision-making, product design, training effectiveness, and audience engagement across industries.
Types Covered:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
Market Dynamics:
Driver:
Rising burden of neurological and mental health disorders
The growing prevalence of neurological and mental health conditions, including ADHD, anxiety, depression, and insomnia, is significantly driving demand for Clinical Neurofeedback Solutions. Increasing awareness of non-invasive and drug-free treatment alternatives has encouraged both patients and healthcare providers to adopt neurofeedback therapies. Additionally, rising stress levels, urban lifestyles, and improved diagnostic capabilities are contributing to higher diagnosis rates. This expanding patient pool, combined with a shift toward personalized and preventive care, continues to strengthen market growth globally.
Restraint:
High cost of devices and therapy
The high cost associated with Clinical Neurofeedback Solutions and therapy sessions remains a key restraint for market expansion. Advanced EEG-based systems require sophisticated hardware, software integration, and professional expertise, leading to elevated pricing. Furthermore, multiple therapy sessions are often needed to achieve desired outcomes, increasing the overall treatment cost for patients. Limited insurance coverage and reimbursement policies in many regions further restrict accessibility. These financial barriers particularly impact adoption in developing economies.
Opportunity:
Technological advancements in brain monitoring
Continuous advancements in brain monitoring technologies present significant opportunities for the market. Innovations in wearable EEG systems, artificial intelligence, and real-time data analytics are enhancing device accuracy, usability, and patient comfort. The integration of mobile applications and cloud-based platforms enables remote monitoring and personalized therapy, expanding access beyond clinical settings. These developments are fostering the emergence of home-based neurofeedback solutions, reducing dependency on healthcare facilities and creating new growth avenues for manufacturers and service providers.
Threat:
Regulatory hurdles and approval delays
Stringent regulatory requirements and prolonged approval timelines pose a major threat to the market. Medical device regulations vary across regions, requiring extensive clinical validation, safety assessments, and compliance documentation. These processes can delay product launches and increase development costs for manufacturers. Additionally, the lack of standardized protocols for neurofeedback therapy raises concerns regarding efficacy and consistency. Such regulatory complexities may discourage new entrants and slow innovation, thereby limiting the overall pace of market expansion.
Covid-19 Impact:
The COVID-19 pandemic had a mixed impact on the market. While initial disruptions in supply chains and reduced clinical visits hindered device adoption, the growing focus on mental health during the pandemic created new opportunities. Increased cases of anxiety, stress, and sleep disorders drove demand for non-invasive therapeutic solutions. Additionally, the shift toward telehealth and remote care accelerated the adoption of home-based neurofeedback systems. This transition highlighted the importance of digital health technologies, supporting long term market growth despite short term challenges.
The HEG Clinical Neurofeedback Solutions segment is expected to be the largest during the forecast period
The HEG Clinical Neurofeedback Solutions segment is expected to account for the largest market share during the forecast period, due to its cost effectiveness and ease of use compared to traditional EEG-based systems. HEG devices measure blood flow and oxygenation in the brain, offering a simpler and more accessible approach to neurofeedback therapy. Their growing adoption in cognitive training, stress management, and educational settings is driving segment growth. Additionally, reduced technical complexity and increasing availability in home based applications further contribute to their widespread utilization.
The epilepsy segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the epilepsy segment is predicted to witness the highest growth rate, due to increasing prevalence of seizure disorders and the need for non-pharmacological treatment options. Neurofeedback therapy offers promising benefits in regulating abnormal brainwave activity associated with epilepsy, reducing seizure frequency in some patients. Growing awareness among healthcare professionals and patients regarding alternative therapies is supporting adoption. Furthermore, ongoing research and clinical studies validating neurofeedback efficacy in epilepsy management are expected to accelerate growth.
Region with largest share:
During the forecast period, the North America region is expected to hold the largest market share, due to rising awareness of mental health, and improving healthcare infrastructure. Rapid urbanization and increasing stress-related disorders are contributing to higher demand for neurofeedback therapies. Additionally, growing investments in healthcare technology, expanding private healthcare facilities, and supportive government initiatives are fostering market growth. The increasing availability of affordable devices and services in emerging economies further strengthens the region’s dominant position.
Region with highest CAGR:
Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, owing to increasing healthcare expenditure, and expanding access to advanced treatment solutions. The rising penetration of digital health platforms and growing acceptance of home-based neurofeedback systems are key growth drivers. Additionally, a strong focus on early diagnosis and preventive healthcare, coupled with a large underserved population, creates significant growth opportunities. Continuous innovation and increasing investments by global and regional players further accelerate market expansion in the region.
Key players in the market
Some of the key players in Clinical Neurofeedback Solutions Market include BrainMaster Technologies, Inc., Thought Technology Ltd., Mind Media B.V., NeuroSky, Inc., Emotiv Inc., Neuroelectrics Corporation, Mitsar Co. Ltd., BEE Medic GmbH, Myndlift Ltd., Muse (InteraXon Inc.), Wearable Sensing, NeuroCare Group GmbH, ANT Neuro B.V., Advanced Brain Monitoring, Inc. and BrainCo, Inc.
Key Developments:
In October 2025, Inception partnered with Brain Co. to co-develop scalable and explainable AI products for enterprises, combining applied research with advanced AI platforms. The collaboration focuses on sectors like healthcare, energy, and public services, delivering trusted, high-impact solutions that enhance decision-making and operational efficiency.
In January 2025, Neuro XR (NXR) partnered with Emotiv to launch emotional heat-mapping technology that combines advanced analytics with EEG data. The solution delivers real-time insights into user emotions, integrating eye-tracking and movement mapping to enhance decision-making, product design, training effectiveness, and audience engagement across industries.
Types Covered:
- EEG Clinical Neurofeedback Solutions
- fNIRS Clinical Neurofeedback Solutions
- HEG Clinical Neurofeedback Solutions
- Other Types
- Attention Deficit Hyperactivity Disorder (ADHD)
- Anxiety Disorders
- Depression
- Epilepsy
- Autism Spectrum Disorders
- Sleep Disorders
- Other Applications
- Hospitals & Clinics
- Research & Academic Institutes
- Home Use
- Other End Users
- North America
- United States
- Canada
- Mexico
- Europe
- United Kingdom
- Germany
- France
- Italy
- Spain
- Netherlands
- Belgium
- Sweden
- Switzerland
- Poland
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Vietnam
- Rest of Asia Pacific
- South America
- Brazil
- Argentina
- Colombia
- Chile
- Peru
- Rest of South America
- Rest of the World (RoW)
- Middle East
- Saudi Arabia
- United Arab Emirates
- Qatar
- Israel
- Rest of Middle East
- Africa
- South Africa
- Egypt
- Morocco
- Rest of Africa
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
- Company Profiling
- Comprehensive profiling of additional market players (up to 3)
- SWOT Analysis of key players (up to 3)
- Regional Segmentation
- Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
- Competitive Benchmarking
- Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances
1 EXECUTIVE SUMMARY
1.1 Market Snapshot and Key Highlights
1.2 Growth Drivers, Challenges, and Opportunities
1.3 Competitive Landscape Overview
1.4 Strategic Insights and Recommendations
2 RESEARCH FRAMEWORK
2.1 Study Objectives and Scope
2.2 Stakeholder Analysis
2.3 Research Assumptions and Limitations
2.4 Research Methodology
2.4.1 Data Collection (Primary and Secondary)
2.4.2 Data Modeling and Estimation Techniques
2.4.3 Data Validation and Triangulation
2.4.4 Analytical and Forecasting Approach
3 MARKET DYNAMICS AND TREND ANALYSIS
3.1 Market Definition and Structure
3.2 Key Market Drivers
3.3 Market Restraints and Challenges
3.4 Growth Opportunities and Investment Hotspots
3.5 Industry Threats and Risk Assessment
3.6 Technology and Innovation Landscape
3.7 Emerging and High-Growth Markets
3.8 Regulatory and Policy Environment
3.9 Impact of COVID-19 and Recovery Outlook
4 COMPETITIVE AND STRATEGIC ASSESSMENT
4.1 Porter's Five Forces Analysis
4.1.1 Supplier Bargaining Power
4.1.2 Buyer Bargaining Power
4.1.3 Threat of Substitutes
4.1.4 Threat of New Entrants
4.1.5 Competitive Rivalry
4.2 Market Share Analysis of Key Players
4.3 Product Benchmarking and Performance Comparison
5 GLOBAL CLINICAL NEUROFEEDBACK SOLUTIONS MARKET, BY TYPE
5.1 EEG Clinical Neurofeedback Solutions
5.2 fNIRS Clinical Neurofeedback Solutions
5.3 HEG Clinical Neurofeedback Solutions
5.4 Other Types
6 GLOBAL CLINICAL NEUROFEEDBACK SOLUTIONS MARKET, BY APPLICATION
6.1 Attention Deficit Hyperactivity Disorder (ADHD)
6.2 Anxiety Disorders
6.3 Depression
6.4 Epilepsy
6.5 Autism Spectrum Disorders
6.6 Sleep Disorders
6.7 Other Applications
7 GLOBAL CLINICAL NEUROFEEDBACK SOLUTIONS MARKET, BY END USER
7.1 Hospitals & Clinics
7.2 Research & Academic Institutes
7.3 Home Use
7.4 Other End Users
8 GLOBAL CLINICAL NEUROFEEDBACK SOLUTIONS MARKET, BY GEOGRAPHY
8.1 North America
8.1.1 United States
8.1.2 Canada
8.1.3 Mexico
8.2 Europe
8.2.1 United Kingdom
8.2.2 Germany
8.2.3 France
8.2.4 Italy
8.2.5 Spain
8.2.6 Netherlands
8.2.7 Belgium
8.2.8 Sweden
8.2.9 Switzerland
8.2.10 Poland
8.2.11 Rest of Europe
8.3 Asia Pacific
8.3.1 China
8.3.2 Japan
8.3.3 India
8.3.4 South Korea
8.3.5 Australia
8.3.6 Indonesia
8.3.7 Thailand
8.3.8 Malaysia
8.3.9 Singapore
8.3.10 Vietnam
8.3.11 Rest of Asia Pacific
8.4 South America
8.4.1 Brazil
8.4.2 Argentina
8.4.3 Colombia
8.4.4 Chile
8.4.5 Peru
8.4.6 Rest of South America
8.5 Rest of the World (RoW)
8.5.1 Middle East
8.5.1.1 Saudi Arabia
8.5.1.2 United Arab Emirates
8.5.1.3 Qatar
8.5.1.4 Israel
8.5.1.5 Rest of Middle East
8.5.2 Africa
8.5.2.1 South Africa
8.5.2.2 Egypt
8.5.2.3 Morocco
8.5.2.4 Rest of Africa
9 STRATEGIC MARKET INTELLIGENCE
9.1 Industry Value Network and Supply Chain Assessment
9.2 White-Space and Opportunity Mapping
9.3 Product Evolution and Market Life Cycle Analysis
9.4 Channel, Distributor, and Go-to-Market Assessment
10 INDUSTRY DEVELOPMENTS AND STRATEGIC INITIATIVES
10.1 Mergers and Acquisitions
10.2 Partnerships, Alliances, and Joint Ventures
10.3 New Product Launches and Certifications
10.4 Capacity Expansion and Investments
10.5 Other Strategic Initiatives
11 COMPANY PROFILES
11.1 BrainMaster Technologies, Inc.
11.2 Thought Technology Ltd.
11.3 Mind Media B.V.
11.4 NeuroSky, Inc.
11.5 Emotiv Inc.
11.6 Neuroelectrics Corporation
11.7 Mitsar Co. Ltd.
11.8 BEE Medic GmbH
11.9 Myndlift Ltd.
11.10 Muse (InteraXon Inc.)
11.11 Wearable Sensing
11.12 NeuroCare Group GmbH
11.13 ANT Neuro b.v.
11.14 Advanced Brain Monitoring, Inc.
11.15 BrainCo, Inc.
1.1 Market Snapshot and Key Highlights
1.2 Growth Drivers, Challenges, and Opportunities
1.3 Competitive Landscape Overview
1.4 Strategic Insights and Recommendations
2 RESEARCH FRAMEWORK
2.1 Study Objectives and Scope
2.2 Stakeholder Analysis
2.3 Research Assumptions and Limitations
2.4 Research Methodology
2.4.1 Data Collection (Primary and Secondary)
2.4.2 Data Modeling and Estimation Techniques
2.4.3 Data Validation and Triangulation
2.4.4 Analytical and Forecasting Approach
3 MARKET DYNAMICS AND TREND ANALYSIS
3.1 Market Definition and Structure
3.2 Key Market Drivers
3.3 Market Restraints and Challenges
3.4 Growth Opportunities and Investment Hotspots
3.5 Industry Threats and Risk Assessment
3.6 Technology and Innovation Landscape
3.7 Emerging and High-Growth Markets
3.8 Regulatory and Policy Environment
3.9 Impact of COVID-19 and Recovery Outlook
4 COMPETITIVE AND STRATEGIC ASSESSMENT
4.1 Porter's Five Forces Analysis
4.1.1 Supplier Bargaining Power
4.1.2 Buyer Bargaining Power
4.1.3 Threat of Substitutes
4.1.4 Threat of New Entrants
4.1.5 Competitive Rivalry
4.2 Market Share Analysis of Key Players
4.3 Product Benchmarking and Performance Comparison
5 GLOBAL CLINICAL NEUROFEEDBACK SOLUTIONS MARKET, BY TYPE
5.1 EEG Clinical Neurofeedback Solutions
5.2 fNIRS Clinical Neurofeedback Solutions
5.3 HEG Clinical Neurofeedback Solutions
5.4 Other Types
6 GLOBAL CLINICAL NEUROFEEDBACK SOLUTIONS MARKET, BY APPLICATION
6.1 Attention Deficit Hyperactivity Disorder (ADHD)
6.2 Anxiety Disorders
6.3 Depression
6.4 Epilepsy
6.5 Autism Spectrum Disorders
6.6 Sleep Disorders
6.7 Other Applications
7 GLOBAL CLINICAL NEUROFEEDBACK SOLUTIONS MARKET, BY END USER
7.1 Hospitals & Clinics
7.2 Research & Academic Institutes
7.3 Home Use
7.4 Other End Users
8 GLOBAL CLINICAL NEUROFEEDBACK SOLUTIONS MARKET, BY GEOGRAPHY
8.1 North America
8.1.1 United States
8.1.2 Canada
8.1.3 Mexico
8.2 Europe
8.2.1 United Kingdom
8.2.2 Germany
8.2.3 France
8.2.4 Italy
8.2.5 Spain
8.2.6 Netherlands
8.2.7 Belgium
8.2.8 Sweden
8.2.9 Switzerland
8.2.10 Poland
8.2.11 Rest of Europe
8.3 Asia Pacific
8.3.1 China
8.3.2 Japan
8.3.3 India
8.3.4 South Korea
8.3.5 Australia
8.3.6 Indonesia
8.3.7 Thailand
8.3.8 Malaysia
8.3.9 Singapore
8.3.10 Vietnam
8.3.11 Rest of Asia Pacific
8.4 South America
8.4.1 Brazil
8.4.2 Argentina
8.4.3 Colombia
8.4.4 Chile
8.4.5 Peru
8.4.6 Rest of South America
8.5 Rest of the World (RoW)
8.5.1 Middle East
8.5.1.1 Saudi Arabia
8.5.1.2 United Arab Emirates
8.5.1.3 Qatar
8.5.1.4 Israel
8.5.1.5 Rest of Middle East
8.5.2 Africa
8.5.2.1 South Africa
8.5.2.2 Egypt
8.5.2.3 Morocco
8.5.2.4 Rest of Africa
9 STRATEGIC MARKET INTELLIGENCE
9.1 Industry Value Network and Supply Chain Assessment
9.2 White-Space and Opportunity Mapping
9.3 Product Evolution and Market Life Cycle Analysis
9.4 Channel, Distributor, and Go-to-Market Assessment
10 INDUSTRY DEVELOPMENTS AND STRATEGIC INITIATIVES
10.1 Mergers and Acquisitions
10.2 Partnerships, Alliances, and Joint Ventures
10.3 New Product Launches and Certifications
10.4 Capacity Expansion and Investments
10.5 Other Strategic Initiatives
11 COMPANY PROFILES
11.1 BrainMaster Technologies, Inc.
11.2 Thought Technology Ltd.
11.3 Mind Media B.V.
11.4 NeuroSky, Inc.
11.5 Emotiv Inc.
11.6 Neuroelectrics Corporation
11.7 Mitsar Co. Ltd.
11.8 BEE Medic GmbH
11.9 Myndlift Ltd.
11.10 Muse (InteraXon Inc.)
11.11 Wearable Sensing
11.12 NeuroCare Group GmbH
11.13 ANT Neuro b.v.
11.14 Advanced Brain Monitoring, Inc.
11.15 BrainCo, Inc.
LIST OF TABLES
Table 1 Global Clinical Neurofeedback Solutions Market Outlook, By Region (2023-2034) ($MN)
Table 2 Global Clinical Neurofeedback Solutions Market Outlook, By Type (2023-2034) ($MN)
Table 3 Global Clinical Neurofeedback Solutions Market Outlook, By EEG Clinical Neurofeedback Solutions (2023-2034) ($MN)
Table 4 Global Clinical Neurofeedback Solutions Market Outlook, By fNIRS Clinical Neurofeedback Solutions (2023-2034) ($MN)
Table 5 Global Clinical Neurofeedback Solutions Market Outlook, By HEG Clinical Neurofeedback Solutions (2023-2034) ($MN)
Table 6 Global Clinical Neurofeedback Solutions Market Outlook, By Other Types (2023-2034) ($MN)
Table 7 Global Clinical Neurofeedback Solutions Market Outlook, By Application (2023-2034) ($MN)
Table 8 Global Clinical Neurofeedback Solutions Market Outlook, By Attention Deficit Hyperactivity Disorder (ADHD) (2023-2034) ($MN)
Table 9 Global Clinical Neurofeedback Solutions Market Outlook, By Anxiety Disorders (2023-2034) ($MN)
Table 10 Global Clinical Neurofeedback Solutions Market Outlook, By Depression (2023-2034) ($MN)
Table 11 Global Clinical Neurofeedback Solutions Market Outlook, By Epilepsy (2023-2034) ($MN)
Table 12 Global Clinical Neurofeedback Solutions Market Outlook, By Autism Spectrum Disorders (2023-2034) ($MN)
Table 13 Global Clinical Neurofeedback Solutions Market Outlook, By Sleep Disorders (2023-2034) ($MN)
Table 14 Global Clinical Neurofeedback Solutions Market Outlook, By Other Applications (2023-2034) ($MN)
Table 15 Global Clinical Neurofeedback Solutions Market Outlook, By End User (2023-2034) ($MN)
Table 16 Global Clinical Neurofeedback Solutions Market Outlook, By Hospitals & Clinics (2023-2034) ($MN)
Table 17 Global Clinical Neurofeedback Solutions Market Outlook, By Research & Academic Institutes (2023-2034) ($MN)
Table 18 Global Clinical Neurofeedback Solutions Market Outlook, By Home Use (2023-2034) ($MN)
Table 19 Global Clinical Neurofeedback Solutions Market Outlook, By Other End Users (2023-2034) ($MN)
Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) are also represented in the same manner as above.
Table 1 Global Clinical Neurofeedback Solutions Market Outlook, By Region (2023-2034) ($MN)
Table 2 Global Clinical Neurofeedback Solutions Market Outlook, By Type (2023-2034) ($MN)
Table 3 Global Clinical Neurofeedback Solutions Market Outlook, By EEG Clinical Neurofeedback Solutions (2023-2034) ($MN)
Table 4 Global Clinical Neurofeedback Solutions Market Outlook, By fNIRS Clinical Neurofeedback Solutions (2023-2034) ($MN)
Table 5 Global Clinical Neurofeedback Solutions Market Outlook, By HEG Clinical Neurofeedback Solutions (2023-2034) ($MN)
Table 6 Global Clinical Neurofeedback Solutions Market Outlook, By Other Types (2023-2034) ($MN)
Table 7 Global Clinical Neurofeedback Solutions Market Outlook, By Application (2023-2034) ($MN)
Table 8 Global Clinical Neurofeedback Solutions Market Outlook, By Attention Deficit Hyperactivity Disorder (ADHD) (2023-2034) ($MN)
Table 9 Global Clinical Neurofeedback Solutions Market Outlook, By Anxiety Disorders (2023-2034) ($MN)
Table 10 Global Clinical Neurofeedback Solutions Market Outlook, By Depression (2023-2034) ($MN)
Table 11 Global Clinical Neurofeedback Solutions Market Outlook, By Epilepsy (2023-2034) ($MN)
Table 12 Global Clinical Neurofeedback Solutions Market Outlook, By Autism Spectrum Disorders (2023-2034) ($MN)
Table 13 Global Clinical Neurofeedback Solutions Market Outlook, By Sleep Disorders (2023-2034) ($MN)
Table 14 Global Clinical Neurofeedback Solutions Market Outlook, By Other Applications (2023-2034) ($MN)
Table 15 Global Clinical Neurofeedback Solutions Market Outlook, By End User (2023-2034) ($MN)
Table 16 Global Clinical Neurofeedback Solutions Market Outlook, By Hospitals & Clinics (2023-2034) ($MN)
Table 17 Global Clinical Neurofeedback Solutions Market Outlook, By Research & Academic Institutes (2023-2034) ($MN)
Table 18 Global Clinical Neurofeedback Solutions Market Outlook, By Home Use (2023-2034) ($MN)
Table 19 Global Clinical Neurofeedback Solutions Market Outlook, By Other End Users (2023-2034) ($MN)
Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) are also represented in the same manner as above.
